CHEMOTHERAPY PROLONGS SURVIVAL IN INOPERABLE PANCREATIC-CARCINOMA
CHEMOTHERAPY PROLONGS SURVIVAL IN INOPERABLE PANCREATIC-CARCINOMA
复制标题
DOI：
10.1002/bjs.1800810629
复制
发表时间：
1994-06-01
影响因子：
9.6
通讯作者：
LEONARD, RCF
中科院分区：
文献类型：
--
作者：
PALMER, KR;KERR, M;LEONARD, RCF
43例无法治愈的晚期胰腺癌患者被随机分组，一组接受由5 - 氟尿嘧啶、阿霉素和丝裂霉素联合的化疗，另一组不接受化疗。就入组时的年龄、疾病程度和身体状况而言，两组匹配良好。化疗的耐受性良好，尽管副作用常见，但通常较轻微。对31例患者基于医院焦虑和抑郁评分进行了心理测量。结果显示，随机分组后即刻以及化疗2个月后，治疗组的抑郁程度明显较轻，但焦虑程度无明显差异。治疗组的中位生存期为33周（范围9 - 80周），而未治疗组为15周（范围1 - 62周）（P < 0.002）。对于所有出现晚期不可手术的胰腺癌患者，都应考虑化疗。
Forty-three patients with irrescetable advanced pancreatic cancer were randomized to receive chemotherapy using a combination of 5-fluorouracil, Adriamycin and mitomycin or no chemotherapy. Groups were well matched with regard to age, extent of disease and performance status on entry. Chemotherapy was well tolerated and, although common, side-effects were usually mild. Psychological measurements based on the Hospital Anxiety and Depression score were made in 31 patients. These showed significantly less depression but not anxiety in the treated group immediately after randomization and following 2 months of chemotherapy. Median survival in the treated group was 33 (range 9-80) weeks compared with 15 (range 1-62) weeks in the untreated group (P < 0.002). Chemotherapy should be considered in all patients presenting with advanced inoperable pancreatic cancer.